Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Diabetes

  Free Subscription


Articles published in Circulation

Retrieve available abstracts of 136 articles:
HTML format



Single Articles


    March 2021
  1. GREEN JB
    Cardiovascular Consequences of Gestational Diabetes.
    Circulation. 2021;143:988-990.
    PubMed    


    February 2021

  2. Correction to: Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
    Circulation. 2021;143:e744.
    PubMed    


  3. YE N, Jardine MJ, Oshima M, Hockham C, et al
    Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial.
    Circulation. 2021 Feb 8. doi: 10.1161/CIRCULATIONAHA.120.048740.
    PubMed     Abstract available


  4. GUNDERSON EP, Sun B, Catov JM, Carnethon M, et al
    Gestational Diabetes History and Glucose Tolerance After Pregnancy Associated With Coronary Artery Calcium in Women During Midlife: The CARDIA Study.
    Circulation. 2021 Feb 1. doi: 10.1161/CIRCULATIONAHA.120.047320.
    PubMed    


    January 2021
  5. JIAN W, Li L, Gui C
    Letter by Jian et al Regarding Article, "Bone Marrow Endothelial Cells Regulate Myelopoiesis in Diabetes Mellitus".
    Circulation. 2021;143:e5-e6.
    PubMed    


  6. NAHRENDORF M
    Response by Nahrendorf to Letter Regarding Article, "Bone Marrow Endothelial Cells Regulate Myelopoiesis in Diabetes Mellitus".
    Circulation. 2021;143:e7-e8.
    PubMed    


    December 2020
  7. DAVE CV, Kim SC, Goldfine AB, Glynn RJ, et al
    Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy.
    Circulation. 2020 Dec 11. doi: 10.1161/CIRCULATIONAHA.120.047965.
    PubMed     Abstract available


  8. CAPODANNO D, Angiolillo DJ
    Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus.
    Circulation. 2020;142:2172-2188.
    PubMed     Abstract available


    November 2020
  9. WRIGHT AK, Suarez-Ortegon MF, Read SH, Kontopantelis E, et al
    Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in Primary and Secondary Prevention Settings.
    Circulation. 2020;142:1925-1936.
    PubMed     Abstract available


  10. FILIPPATOS G, Anker SD, Agarwal R, Pitt B, et al
    Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes.
    Circulation. 2020 Nov 16. doi: 10.1161/CIRCULATIONAHA.120.051898.
    PubMed     Abstract available


  11. SHIM CY, Seo J, Cho I, Lee CJ, et al
    Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.
    Circulation. 2020 Nov 13. doi: 10.1161/CIRCULATIONAHA.120.051992.
    PubMed    


  12. LEE MMY, Brooksbank KJM, Wetherall K, Mangion K, et al
    Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
    Circulation. 2020 Nov 13. doi: 10.1161/CIRCULATIONAHA.120.052186.
    PubMed     Abstract available


  13. ANKER SD, Butler J, Filippatos G, Khan MS, et al
    Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial.
    Circulation. 2020 Nov 11. doi: 10.1161/CIRCULATIONAHA.120.051824.
    PubMed     Abstract available


  14. PATEL KV, Bahnson JL, Gaussoin SA, Johnson KC, et al
    Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of Heart Failure and Myocardial Infarction in Type 2 Diabetes: Findings From the Look AHEAD Trial.
    Circulation. 2020 Nov 9. doi: 10.1161/CIRCULATIONAHA.120.050941.
    PubMed    



  15. Correction to: Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Circulation. 2020;142:e316.
    PubMed    


  16. PONSFORD MJ, Gkatzionis A, Walker VM, Grant AJ, et al
    Cardiometabolic Traits, Sepsis, and Severe COVID-19: A Mendelian Randomization Investigation.
    Circulation. 2020;142:1791-1793.
    PubMed    


    October 2020

  17. Correction to: Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease A Scientific Statement From the American Heart Association.
    Circulation. 2020;142:e304.
    PubMed    


  18. FRANCHI F, Rollini F, Been L, Briceno M, et al
    Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention
    Circulation. 2020;142:1500-1502.
    PubMed    


  19. COSENTINO F, Cannon CP, Cherney DZI, Masiukiewicz U, et al
    Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Circulation. 2020 Oct 7. doi: 10.1161/CIRCULATIONAHA.120.050255.
    PubMed     Abstract available


    September 2020
  20. RANGASWAMI J, Bhalla V, de Boer IH, Staruschenko A, et al
    Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.
    Circulation. 2020 Sep 28:CIR0000000000000920. doi: 10.1161/CIR.0000000000000920.
    PubMed     Abstract available


  21. FOX SE, Li G, Akmatbekov A, Harbert JL, et al
    Unexpected Features of Cardiac Pathology in COVID-19 Infection.
    Circulation. 2020;142:1123-1125.
    PubMed    


  22. ZELNIKER TA, Raz I, Sabatine MS, Wiviott SD, et al
    Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial".
    Circulation. 2020;142:e129-e130.
    PubMed    


  23. CHEN ZQ, Chen F, Li L
    Letter by Chen et al Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial".
    Circulation. 2020;142:e127-e128.
    PubMed    


    August 2020
  24. MORDI NA, Mordi IR, Singh JS, McCrimmon RJ, et al
    Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Circulation. 2020 Aug 29. doi: 10.1161/CIRCULATIONAHA.120.048739.
    PubMed     Abstract available


  25. GAN L, Xie D, Lau WB, Ma XL, et al
    Response by Gan et al to Letter Regarding Article, "Small Extracellular Microvesicles Mediated Pathological Communications Between Dysfunctional Adipocytes and Cardiomyocytes as a Novel Mechanism Exacerbating Ischemia/Reperfusion Injury in Diabetic Mi
    Circulation. 2020;142:e99-e100.
    PubMed    


  26. REN C, Chen H, Xie Y
    Letter by Ren et al Regarding Article, "Small Extracellular Microvesicles Mediated Pathological Communications Between Dysfunctional Adipocytes and Cardiomyocytes as a Novel Mechanism Exacerbating Ischemia/Reperfusion Injury in Diabetic Mice".
    Circulation. 2020;142:e97-e98.
    PubMed    


  27. LI Y, Ding F, Shen Z
    Letter by Li et al Regarding Article, "Small Extracellular Microvesicles Mediated Pathological Communications Between Dysfunctional Adipocytes and Cardiomyocytes as a Novel Mechanism Exacerbating Ischemia/Reperfusion Injury in Diabetic Mice".
    Circulation. 2020;142:e95-e96.
    PubMed    


    July 2020
  28. HAYNES N, Cooper LA, Albert MA
    At the Heart of the Matter: Unmasking and Addressing the Toll of COVID-19 on Diverse Populations.
    Circulation. 2020;142:105-107.
    PubMed    


    June 2020
  29. POTPARA TS, Lip GYH
    Combining Anticoagulant and Antiplatelet Therapies for Chronic Atherosclerotic Disease: A Focus on Diabetes Mellitus as a High-Risk Patient Group.
    Circulation. 2020;141:1855-1858.
    PubMed    


    April 2020
  30. BETHEL MA, Stevens SR, Buse JB, Choi J, et al
    Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
    Circulation. 2020;141:1360-1370.
    PubMed     Abstract available


  31. HOYER FF, Zhang X, Coppin E, Vasamsetti SB, et al
    Bone Marrow Endothelial Cells Regulate Myelopoiesis in Diabetes.
    Circulation. 2020 Apr 22. doi: 10.1161/CIRCULATIONAHA.120.046038.
    PubMed     Abstract available


  32. GRANGER CB, Mahaffey KW
    Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus.
    Circulation. 2020;141:1235-1237.
    PubMed    


  33. ARNOLD SV, Bhatt DL, Barsness GW, Beatty AL, et al
    Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association.
    Circulation. 2020 Apr 13:CIR0000000000000766. doi: 10.1161/CIR.0000000000000766.
    PubMed     Abstract available


  34. FRIED JA, Ramasubbu K, Bhatt R, Topkara VK, et al
    The Variety of Cardiovascular Presentations of COVID-19.
    Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164.
    PubMed    


    March 2020
  35. SOUSA GR, Kosiborod M, Bluemke DA, Lipes MA, et al
    Cardiac Autoimmunity Is Associated With Subclinical Myocardial Dysfunction in Patients With Type 1 Diabetes Mellitus.
    Circulation. 2020;141:1107-1109.
    PubMed    


  36. BHATT DL, Eikelboom JW, Connolly SJ, Steg PG, et al
    The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial.
    Circulation. 2020 Mar 28. doi: 10.1161/CIRCULATIONAHA.120.046448.
    PubMed     Abstract available


  37. PANDEY A, Patel KV, Bahnson JL, Gaussoin SA, et al
    Association of Intensive Lifestyle Intervention, Fitness and Body Mass Index with Risk of Heart Failure in Overweight or Obese Adults with Type 2 Diabetes Mellitus: An Analysis from the Look AHEAD Trial.
    Circulation. 2020 Mar 5. doi: 10.1161/CIRCULATIONAHA.119.044865.
    PubMed     Abstract available


  38. TSUDA K
    Letter by Tsuda Regarding Article, "Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial".
    Circulation. 2020;141:e100-e101.
    PubMed    


    January 2020
  39. SHARMA A, Pagidipati NJ, Califf RM, McGuire DK, et al
    Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
    Circulation. 2020 Jan 29. doi: 10.1161/CIRCULATIONAHA.119.041022.
    PubMed     Abstract available


  40. BERGMARK BA, Bhatt DL, McGuire DK, Scirica BM, et al
    Response by Bergmark et al to Letter Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial".
    Circulation. 2020;141:e57-e58.
    PubMed    


  41. MORDI IR, Mohan M, Lang CC
    Letter by Mordi et al Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial".
    Circulation. 2020;141:e55-e56.
    PubMed    


  42. ZELNIKER TA, Bonaca MP, Furtado R, Mosenzon O, et al
    Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial.
    Circulation. 2020 Jan 27. doi: 10.1161/CIRCULATIONAHA.119.044183.
    PubMed     Abstract available


  43. GAN L, Xie D, Liu J, Lau WB, et al
    Small Extracellular Microvesicles Mediated Pathological Communications between Dysfunctional Adipocytes and Cardiomyocytes as a Novel Mechanisms Exacerbating Ischemia/Reperfusion Injury in Diabetic Mice.
    Circulation. 2020 Jan 10. doi: 10.1161/CIRCULATIONAHA.119.042640.
    PubMed     Abstract available


    December 2019
  44. BUTLER J, Packer M, Greene SJ, Fiuzat M, et al
    Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.
    Circulation. 2019;140:2108-2118.
    PubMed     Abstract available


  45. GRANDI SM, Smith GN, Platt RW
    The Relative Contribution of Pregnancy Complications to Cardiovascular Risk Prediction: Are We Getting It Wrong?
    Circulation. 2019;140:1965-1967.
    PubMed    


    November 2019
  46. PETRIE MC
    Sodium Glucose Cotransporter 2 Inhibitors: Searching for Mechanisms in the Wake of Large, Positive Cardiovascular Outcomes Trials.
    Circulation. 2019;140:1703-1705.
    PubMed    


  47. ARNOTT C, Neal B
    Do GLP-1 Receptor Agonists Care if You Have Heart Failure?
    Circulation. 2019;140:1623-1625.
    PubMed    


  48. CANNON CP, Perkovic V, Agarwal R, Baldassarre J, et al
    Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.
    Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044359.
    PubMed     Abstract available


  49. MAZER CD, Hare GMT, Connelly PW, Gilbert RE, et al
    Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease.
    Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044235.
    PubMed     Abstract available


    October 2019
  50. ELGHAZALY H, Hajiev S, Singh P
    Letter by Elghazaly et al Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
    Circulation. 2019;140:e738-e739.
    PubMed    


  51. KATO ET, Sabatine MS, Wiviott SD
    Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
    Circulation. 2019;140:e740-e741.
    PubMed    


  52. SATTAR N, Rawshani A, Franzen S
    Response by Sattar et al to Letters Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
    Circulation. 2019;140:e724-e725.
    PubMed    


  53. WANG J, Xu Y
    Letter by Wang and Xu Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
    Circulation. 2019;140:e722-e723.
    PubMed    


  54. WANG D, Chen T, Yang X
    Letter by Wang et al Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
    Circulation. 2019;140:e720-e721.
    PubMed    


  55. GODOY LC, Rao V, Farkouh ME
    Coronary Revascularization of Patients With Diabetes Mellitus in the Setting of Acute Coronary Syndromes.
    Circulation. 2019;140:1233-1235.
    PubMed    


  56. ZIMMET PZ, Rutherford JD
    Reflections on the Evolving Global Diabetes Epidemic: A Conversation With Paul Z. Zimmet, MBBS, MD, PhD.
    Circulation. 2019;140:1140-1144.
    PubMed    


  57. BARRETT TJ, Distel E, Murphy AJ, Hu J, et al
    Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation.
    Circulation. 2019;140:1170-1184.
    PubMed     Abstract available


  58. RADER DJ
    Enhancing Atherosclerosis Regression in Diabetic Mice Through Apo AI (Apolipoprotein AI).
    Circulation. 2019;140:1185-1187.
    PubMed    


  59. DIAZ R, Tajer C
    Current Status and Future Strategies for Cardiovascular Disease in Argentina.
    Circulation. 2019;140:1137-1139.
    PubMed    


    September 2019
  60. FUDIM M, White J, Pagidipati NJ, Lokhnygina Y, et al
    Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Circulation. 2019 Sep 23. doi: 10.1161/CIRCULATIONAHA.119.041659.
    PubMed     Abstract available



  61. Correction to: Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America.
    Circulation. 2019;140:e692.
    PubMed    


  62. NASSIF ME, Windsor S, Tang F, Khariton Y, et al
    Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Circulation. 2019 Sep 16. doi: 10.1161/CIRCULATIONAHA.119.042929.
    PubMed    


    August 2019
  63. BERG DD, Wiviott SD, Scirica BM, Gurmu Y, et al
    Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Circulation. 2019 Aug 31. doi: 10.1161/CIRCULATIONAHA.119.042685.
    PubMed    


  64. VERMA S, Mazer CD, Yan AT, Mason T, et al
    Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Circulation. 2019 Aug 22. doi: 10.1161/CIRCULATIONAHA.119.042375.
    PubMed     Abstract available


  65. SANCHEZ EJ, Cefalu WT
    Know Diabetes by Heart.
    Circulation. 2019;140:526-528.
    PubMed    


  66. PACKER M
    Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
    Circulation. 2019;140:443-445.
    PubMed    


    July 2019
  67. BERGMARK BA, Bhatt DL, McGuire DK, Cahn A, et al
    Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial.
    Circulation. 2019 Jul 31. doi: 10.1161/CIRCULATIONAHA.119.040144.
    PubMed     Abstract available


  68. MORRIS DR, Sherliker P, Clack R, Preiss D, et al
    Opposite Associations of Aortic Aneurysm With Blood Glucose and With Diabetes Mellitus.
    Circulation. 2019;140:264-266.
    PubMed    


  69. MAHAFFEY KW, Jardine MJ, Bompoint S, Cannon CP, et al
    Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial.
    Circulation. 2019 Jul 11. doi: 10.1161/CIRCULATIONAHA.119.042007.
    PubMed     Abstract available


    June 2019
  70. KRONLAGE M, Dewenter M, Grosso J, Fleming T, et al
    O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart from Failure.
    Circulation. 2019 Jun 14. doi: 10.1161/CIRCULATIONAHA.117.031942.
    PubMed     Abstract available


  71. ARNOLD SV, de Lemos JA, Rosenson RS, Ballantyne CM, et al
    Use of Guideline-Recommended Risk-Reduction Strategies Among Patients with Diabetes and Atherosclerotic Cardiovascular Disease: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOUL
    Circulation. 2019 Jun 7. doi: 10.1161/CIRCULATIONAHA.119.041730.
    PubMed     Abstract available


  72. DUNLAY SM, Givertz MM, Aguilar D, Allen LA, et al
    Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America.
    Circulation. 2019 Jun 6:CIR0000000000000691. doi: 10.1161/CIR.0000000000000691.
    PubMed     Abstract available


    May 2019
  73. MANN JFE, Fonseca V, Mosenzon O, Raz I, et al
    Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".
    Circulation. 2019;139:e1017-e1018.
    PubMed    


  74. XIE J, Jiang M, Li L
    Letter by Xie et al Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".
    Circulation. 2019;139:e1015-e1016.
    PubMed    


  75. NYSTROM T, Sartipy U, Contardi A, Lind M, et al
    Glycated Hemoglobin A1c Levels in Type 1 Diabetes Mellitus and Outcomes After Myocardial Infarction.
    Circulation. 2019;139:2380-2382.
    PubMed    


    April 2019
  76. JAMERSON KA
    Should Certain Antihyperglycemic Medications Be Preferred Over Antihypertensive Medications for Blood Pressure Control in Special Populations With Diabetes Mellitus?
    Circulation. 2019;139:2110-2112.
    PubMed    


  77. WRIGHT AK, Kontopantelis E, Emsley R, Buchan IE, et al
    Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes: A Population-Based Cohort Study Assessing Sex Disparities.
    Circulation. 2019 Apr 15. doi: 10.1161/CIRCULATIONAHA.118.039100.
    PubMed     Abstract available


  78. SATTAR N, Rawshani A, Franzen S, Rawshani A, et al
    Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks Findings From the Swedish National Diabetes Registry.
    Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.037885.
    PubMed    


  79. LOW WANG CC, Everett BM, Burman KD, Wilson PWF, et al
    Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs?
    Circulation. 2019;139:1741-1743.
    PubMed    


    March 2019
  80. FURTADO RHM, Bonaca MP, Raz I, Zelniker TA, et al
    Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial.
    Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.039996.
    PubMed     Abstract available


  81. KATO ET, Silverman MG, Mosenzon O, Zelniker TA, et al
    Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.040130.
    PubMed     Abstract available


  82. FIGTREE GA, Radholm K, Barrett TD, Perkovic V, et al
    Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program.
    Circulation. 2019 Mar 17. doi: 10.1161/CIRCULATIONAHA.119.040057.
    PubMed     Abstract available


    February 2019
  83. RAWSHANI A, Rawshani A, Sattar N, Franzen S, et al
    Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes.
    Circulation. 2019 Feb 25. doi: 10.1161/CIRCULATIONAHA.118.037454.
    PubMed     Abstract available


  84. FERDINAND KC, Izzo JL, Lee J, Meng L, et al
    Antihyperglycemic and Blood Pressure Effects of Empagliflozin in African Americans with Type 2 Diabetes and Hypertension.
    Circulation. 2019 Feb 21. doi: 10.1161/CIRCULATIONAHA.118.036568.
    PubMed     Abstract available


  85. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of
    Circulation. 2019 Feb 21. doi: 10.1161/CIRCULATIONAHA.118.038868.
    PubMed     Abstract available


  86. PETERS SAE, Muntner P, Woodward M
    Sex Differences in the Prevalence of, and Trends in, Cardiovascular Risk Factors, Treatment, and Control in the United States, 2001 to 2016.
    Circulation. 2019;139:1025-1035.
    PubMed     Abstract available


  87. KIDOKORO K, Cherney DZI, Bozovic A, Nagasu H, et al
    Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice using In Vivo Imaging.
    Circulation. 2019 Feb 18. doi: 10.1161/CIRCULATIONAHA.118.037418.
    PubMed     Abstract available


  88. PETRIE JR, Sattar N
    Excess Cardiovascular Risk in Type 1 Diabetes Mellitus.
    Circulation. 2019;139:744-747.
    PubMed    


    January 2019
  89. WU S, Lu Q, Ding Y, Wu Y, et al
    Hyperglycemia-Driven Inhibition of AMP-Activated Protein Kinase alpha2 Induces Diabetic Cardiomyopathy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes in vivo.
    Circulation. 2019 Jan 16. doi: 10.1161/CIRCULATIONAHA.118.033552.
    PubMed     Abstract available


  90. FIGTREE GA, Radholm K, Neal B
    Response by Figtree et al to Letter Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".
    Circulation. 2019;139:418-419.
    PubMed    


  91. KOH KK
    Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".
    Circulation. 2019;139:416-417.
    PubMed    


  92. ZANNAD F, Rossignol P
    Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure.
    Circulation. 2019;139:362-365.
    PubMed    


  93. GREENE SJ, Butler J
    Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Circulation. 2019;139:152-154.
    PubMed    


    December 2018
  94. BJORNSTAD P, Schafer M, Truong U, Cree-Green M, et al
    Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus.
    Circulation. 2018;138:2895-2907.
    PubMed     Abstract available


  95. MANN JFE, Fonseca V, Mosenzon O, Raz I, et al
    Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Circulation. 2018;138:2908-2918.
    PubMed     Abstract available


  96. VERMA S, Poulter NR, Bhatt DL, Bain SC, et al
    Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
    Circulation. 2018;138:2884-2894.
    PubMed     Abstract available


    November 2018
  97. KARIO K, Okada K, Kato M, Nishizawa M, et al
    24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study.
    Circulation. 2018 Nov 29. doi: 10.1161/CIRCULATIONAHA.118.037076.
    PubMed     Abstract available


  98. SOUSA GR, Pober D, Galderisi A, Lv H, et al
    Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus: A DCCT/EDIC Cohort-Based Study.
    Circulation. 2018 Nov 26. doi: 10.1161/CIRCULATIONAHA.118.036068.
    PubMed     Abstract available


  99. MCGUIRE DK, Alexander JH, Johansen OE, Perkovic V, et al
    Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    Circulation. 2018 Nov 11. doi: 10.1161/CIRCULATIONAHA.118.038352.
    PubMed     Abstract available


    October 2018
  100. DONZELLI A, Schivalocchi A, Giudicatti G
    Letter by Donzelli et al Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Effica
    Circulation. 2018;138:1912-1913.
    PubMed    


  101. KOH KK
    Letter by Koh Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy Internat
    Circulation. 2018;138:1914-1915.
    PubMed    


  102. INZUCCHI SE, Kosiborod M, Fitchett D, Wanner C, et al
    Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
    Circulation. 2018;138:1904-1907.
    PubMed    


  103. KHERA A, Budoff MJ, O'Donnell CJ, Ayers CA, et al
    Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator.
    Circulation. 2018;138:1819-1827.
    PubMed     Abstract available


  104. VERMA S, Leiter LA, Mazer CD, Bain SC, et al
    Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
    Circulation. 2018;138:1605-1607.
    PubMed    


  105. CLAGGETT B, Lachin JM, Hantel S, Fitchett D, et al
    Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.
    Circulation. 2018;138:1599-1601.
    PubMed    


    September 2018
  106. MADIAS JE
    Letter by Madias Regarding Article, "Long-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury".
    Circulation. 2018;138:1176-1177.
    PubMed    


  107. CHAPMAN AR, Mills NL
    Response To Letter Regarding Article "Long-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury".
    Circulation. 2018;138:1178.
    PubMed    


    August 2018
  108. TAMPAKIS A, Tampaki EC, Gurke L
    Letter by Tampakis et al Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Circulation. 2018;138:848-849.
    PubMed    


  109. WANNER C, von Eynatten M, Zinman B
    Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Circulation. 2018;138:850-851.
    PubMed    


  110. KOH KK
    Letter by Koh Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Circulation. 2018;138:846-847.
    PubMed    


    July 2018
  111. SATTAR N, McGuire DK
    Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink.
    Circulation. 2018;138:7-9.
    PubMed    


    June 2018
  112. MCALLISTER DA, Read S, Kerssens J, Livingstone S, et al
    Incidence of Hospitalisation for Heart Failure and Case-Fatality Among 3.25 Million People with and without Diabetes.
    Circulation. 2018 Jun 27. pii: CIRCULATIONAHA.118.034986.
    PubMed     Abstract available


  113. YOUNG LH, Viscoli CM, Schwartz GG, Inzucchi SE, et al
    Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone.
    Circulation. 2018 Jun 22. pii: CIRCULATIONAHA.118.034763.
    PubMed     Abstract available


    May 2018
  114. VERMA S, Bhatt DL, Bain SC, Buse JB, et al
    Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
    Circulation. 2018;137:2179-2183.
    PubMed    


  115. PACKER M
    Response by Packer to Letter Regarding Article, "Activation and Inhibition of Sodium-Hydrogen Exchange Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure".
    Circulation. 2018;137:1981-1982.
    PubMed    


  116. GAZMURI RJ, Karmazyn M
    Letter by Gazmuri and Karmazyn Regarding Article, "Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure".
    Circulation. 2018;137:1979-1980.
    PubMed    


    April 2018
  117. HU L, Qi Z, Zhang S, Luo X, et al
    Response by Hu et al to Letters Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus".
    Circulation. 2018;137:1877-1878.
    PubMed    


  118. GONG L, Li J, Yang G
    Letter by Gong et al Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus".
    Circulation. 2018;137:1875-1876.
    PubMed    


  119. JIN-SHAN H, Xue-Bin L
    Letter by Jin-shan and Xue-bin Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus".
    Circulation. 2018;137:1874.
    PubMed    


    March 2018
  120. RADHOLM K, Figtree G, Perkovic V, Solomon SD, et al
    Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Circulation. 2018 Mar 11. pii: CIRCULATIONAHA.118.034222.
    PubMed     Abstract available


  121. VIJAYAKUMAR S, Vaduganathan M, Butler J
    Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions.
    Circulation. 2018;137:1060-1073.
    PubMed     Abstract available


    January 2018
  122. IANIRO G, Cammarota G, Gasbarrini A
    Letter by Ianiro et al Regarding Article, "Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium".
    Circulation. 2018;137:213-214.
    PubMed    


  123. PLUTZKY J, Bakris G
    Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
    Circulation. 2018;137:130-133.
    PubMed    


    December 2017
  124. GIUGLIANO RP, Cannon CP, Blazing MA, Nicolau JC, et al
    Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT.
    Circulation. 2017 Dec 20. pii: CIRCULATIONAHA.117.030950.
    PubMed     Abstract available


    November 2017
  125. VERMA S, Mazer CD, Al-Omran M, Inzucchi SE, et al
    Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
    Circulation. 2017 Nov 13. pii: CIRCULATIONAHA.117.032031.
    PubMed     Abstract available


    October 2017
  126. LYTVYN Y, Bjornstad P, Udell JA, Lovshin JA, et al
    Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Circulation. 2017;136:1643-1658.
    PubMed     Abstract available


  127. YOUNG LH, Viscoli CM, Inzucchi SE, Kernan WN, et al
    Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
    Circulation. 2017;136:1567-1568.
    PubMed    


  128. JIN-SHAN H, Xue-Bin L
    Letter by Jin-Shan and Xue-Bin Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
    Circulation. 2017;136:1565-1566.
    PubMed    


  129. MUSSO G, Cassader M, Gambino R
    Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
    Circulation. 2017;136:1563-1564.
    PubMed    


  130. WOLSK E, Claggett B, Diaz R, Dickstein K, et al
    Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
    Circulation. 2017;136:1560-1562.
    PubMed    


  131. PACKER M
    Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure.
    Circulation. 2017;136:1548-1559.
    PubMed     Abstract available


  132. BUTLER J, Anker SD
    The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
    Circulation. 2017;136:1459-1461.
    PubMed    


    September 2017
  133. WILSON PWF, Gagnon D
    Diabetes Mellitus and Control of Cardiovascular Disease Risk Factors: A Challenge to Improve Usual Care.
    Circulation. 2017;136:1204-1206.
    PubMed    


  134. STRIEPE K, Jumar A, Ott C, Karg MV, et al
    Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
    Circulation. 2017;136:1167-1169.
    PubMed    


  135. WANNER C, Lachin JM, Inzucchi SE, Fitchett D, et al
    Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes, Established Cardiovascular Disease and Chronic Kidney Disease.
    Circulation. 2017 Sep 13. pii: CIRCULATIONAHA.117.028268.
    PubMed     Abstract available


    August 2017
  136. NAUCK MA, Meier JJ, Cavender MA, Abd El Aziz M, et al
    Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Circulation. 2017;136:849-870.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: